---
title: "SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292662482.md"
description: "A robust, innovation-driven pipeline is advancing with multiple late-stage and early-stage assets in hematology, oncology, and rare diseases. Key near-term catalysts include pivotal trial readouts in GVHD and IPF, and new clinical programs in myelofibrosis and EGFR-mutant lung cancer, supported by strong financials and strategic collaborations.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-14T17:59:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292662482.md)
  - [en](https://longbridge.com/en/news/292662482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292662482.md)
generator: "portal-rs"
---

# SNDX: Multiple late-stage and novel assets drive growth, with key data readouts expected in 2024–2025

A robust, innovation-driven pipeline is advancing with multiple late-stage and early-stage assets in hematology, oncology, and rare diseases. Key near-term catalysts include pivotal trial readouts in GVHD and IPF, and new clinical programs in myelofibrosis and EGFR-mutant lung cancer, supported by strong financials and strategic collaborations.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)

## Related News & Research

- [Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand](https://longbridge.com/en/news/294864349.md)
- [SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027](https://longbridge.com/en/news/292631585.md)
- [Active Biotech wins European regulatory approval to resume tasquinimod myelofibrosis trial enrollment](https://longbridge.com/en/news/296500289.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [SoftBank CISO Iida says sovereign AI push aims to keep customer data within Japan](https://longbridge.com/en/news/296442282.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**